Can Low-Dose combo tame tough blood pressure in kidney disease?
NCT ID NCT07645300
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether low doses of two older blood pressure drugs, spironolactone and chlorthalidone, can safely lower blood pressure in people with moderate to advanced chronic kidney disease (CKD). About 160 U.S. Veterans with CKD and high blood pressure will take the drugs alone or together for up to 12 weeks. The goal is to find effective treatment options that manage blood pressure without causing dangerous side effects like high potassium levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2032
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Study is limited to US Veterans * GFR estimated by race-independent CKD-EPI formula \< 45 ml/min/1.73m2 but 15 mL/min/1.73m2 * Hypertension * The investigators will use clinic AOBP of at least 135/85 to define hypertension * Treatment with antihypertensive drugs * This would require the use of at least one antihypertensive drug * One of the drugs should be either an ACE inhibitor or ARB or a beta-blocker at the time of randomization * Serum K 3.5 to 5.2 mEq/L at the time of randomization Exclusion Criteria: * Clinic AOBP of \>=160/100 mmHg * Use of: * SPL * eplerenone * amiloride * triamterene * finerenone * thiazide * thiazide-like drugs (CTD, HCTZ, metolazone, indapamide) or the use of K binders or fludrocortisone in the previous 4 weeks * K supplementation would be allowed * Myocardial infarction, heart failure hospitalization, or stroke 8 weeks prior to randomization * If the patient is only on an alpha blocker, as the sole antihypertensive drug, they will be excluded * Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception * Known hypersensitivity or a prior documented adverse reaction to CTD or SPL
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease, 3B and 4 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana, 46202-2884, United States